CABFIDENCE: Global Real-World Evidence Cohort Study to evaluate Utilization, Clinical and Patient-Reported Outcomes among CAB+RPV LA users (224047) First published 12/06/2025 Last updated 08/10/2025 EU PAS number:EUPAS1000000616 Study Planned
Call Center EU GSK Clinical Trials RD.CTT-globalmailbox@gsk.comStudy contactRD.CTT-globalmailbox@gsk.com